{"product_id":"ogi-vrio-analysis","title":"OrganiGram Holdings Inc. (OGI): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs OrganiGram Holdings Inc. (OGI) truly built for sustained success? This VRIO analysis cuts straight to the core, dissecting the firm's resources based on their Value, Rarity, Inimitability, and Organization to uncover the true source of its competitive advantage - or lack thereof. Dive in below to see the definitive verdict on whether OrganiGram Holdings Inc. (OGI)'s assets translate into lasting market dominance.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrganiGram Holdings Inc. (OGI) - VRIO Analysis: Canadian Recreational Market Share Leadership\n\u003c\/h2\u003e\n\u003cp\u003eYou're looking at OrganiGram Holdings Inc.'s dominant position in the Canadian adult-use cannabis space, and frankly, it's the engine driving their recent financial turnaround. The market share leadership isn't just a vanity metric; it's translating directly into dollars, as seen in their Q3 Fiscal 2025 results. We need to assess if this lead is truly defensible.\u003c\/p\u003e\n\n\u003cp\u003eThe numbers from Q3 Fiscal 2025 are clear: OrganiGram Holdings Inc. posted record net revenue of \u003cstrong\u003e$70.8 million\u003c\/strong\u003e, a \u003cstrong\u003e72%\u003c\/strong\u003e jump year-over-year, with recreational sales making up \u003cstrong\u003e85%\u003c\/strong\u003e of that, or \u003cstrong\u003e$59.9 million\u003c\/strong\u003e. This performance is built on being the top dog in key, high-velocity categories across the country.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Revenue Translation from Market Dominance\u003c\/h3\u003e\n\u003cp\u003eValue is high because market leadership directly fuels the top line. OrganiGram Holdings Inc. is the undisputed national leader in Canada, which is a mature market that grew \u003cstrong\u003e6.6%\u003c\/strong\u003e year-over-year to reach \u003cstrong\u003e$1.4 billion\u003c\/strong\u003e in retail sales in Q3 Fiscal 2025. Their overall national market share stands at \u003cstrong\u003e11.6%\u003c\/strong\u003e, giving them a \u003cstrong\u003e2.5 point\u003c\/strong\u003e lead over the next closest competitor. This scale is what helped them achieve \u003cstrong\u003e$5.7 million\u003c\/strong\u003e in Adjusted EBITDA that quarter.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick breakdown of where that value is concentrated:\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e#1 in Vapes segment share: \u003cstrong\u003e20.4%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e#1 in Pre-rolls segment share: \u003cstrong\u003e8.3%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e#1 in Milled Flower segment share\u003c\/li\u003e\n\u003cli\u003e#1 in Concentrates segment share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIf you can't sell product, nothing else matters. They are selling.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: The Difficulty of National #1 Status\u003c\/h3\u003e\n\u003cp\u003eRarity is high here. Achieving the number one spot nationally in a fragmented, regulated market like Canada is tough. It means you've successfully navigated provincial listing requirements and consumer preferences better than everyone else, including competitors with deep pockets. While they are only \u003cstrong\u003e#3\u003c\/strong\u003e in edibles and dried flower, their dominance in the high-growth vape and pre-roll categories makes this position rare.\u003c\/p\u003e\n\u003cp\u003eWhat this estimate hides is that market share can be fleeting; a single major product flop can erode this quickly. Still, being the national leader is not something you can buy overnight.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Distribution and Brand Equity Hurdles\u003c\/h3\u003e\n\u003cp\u003eImitability is moderate to high. The market share itself can be copied if a competitor launches a killer product, but replicating the underlying infrastructure is the real barrier. OrganiGram Holdings Inc.'s established relationships with provincial distributors and retailers - the physical shelf space - are not easily duplicated. It takes years and significant capital to secure those prime spots.\u003c\/p\u003e\n\u003cp\u003eThe distribution network supporting their leadership is the moat. It took them time to build this logistical web across the provinces. It's defintely not a simple copy-paste job for a rival.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Capitalizing on the Lead\u003c\/h3\u003e\n\u003cp\u003eOrganization is high because the results prove they are structured to execute on this advantage. They are not just holding market share; they are growing revenue off it. Evidence includes achieving \u003cstrong\u003e$5.0 million\u003c\/strong\u003e in positive Free Cash Flow in Q3 Fiscal 2025, a significant shift from a negative \u003cstrong\u003e$4.8 million\u003c\/strong\u003e the prior year. Furthermore, the successful integration of Motif Labs, which has already delivered \u003cstrong\u003e$4.2 million\u003c\/strong\u003e in synergies toward a \u003cstrong\u003e$15 million\u003c\/strong\u003e target, shows management is organized to extract maximum value from their assets.\u003c\/p\u003e\n\u003cp\u003eThe company's structure is clearly geared toward leveraging domestic strength for international gain, evidenced by international revenue surging \u003cstrong\u003e208%\u003c\/strong\u003e year-over-year to \u003cstrong\u003e$7.4 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage Assessment\u003c\/h3\u003e\n\u003cp\u003eThe competitive advantage here is \u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e, but it requires constant vigilance. The combination of high value (market leadership), rarity (national #1 status), and moderate-to-high inimitability (distribution network) creates a strong position. To keep it sustained, OrganiGram Holdings Inc. must continue to innovate, as they are targeting a \u003cstrong\u003e40%\u003c\/strong\u003e adjusted gross margin by the second half of FY2026. If product relevance wanes, the distribution advantage alone won't save them.\u003c\/p\u003e\n\u003cp\u003eHere is the summary scoring based on the analysis:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eKey Supporting Data (Q3 FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003e#1 in Vapes\/Pre-rolls; Net Revenue of \u003cstrong\u003e$70.8 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003e#1 National LP with \u003cstrong\u003e11.6%\u003c\/strong\u003e share and \u003cstrong\u003e2.5 point\u003c\/strong\u003e lead\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eDifficult\/Costly\u003c\/td\u003e\n\u003ctd\u003eEstablished national distribution network\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003ePositive FCF of \u003cstrong\u003e$5.0 million\u003c\/strong\u003e; successful synergy capture\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Implication\u003c\/td\u003e\n\u003ctd\u003eSustained Competitive Advantage\u003c\/td\u003e\n\u003ctd\u003eRequires continued product relevance and margin expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrganiGram Holdings Inc. (OGI) - VRIO Analysis: Proprietary FAST™ Nanoemulsion Technology (Edison Sonics)\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis below is based on preliminary clinical study data and product launch information related to the FAST™ Nanoemulsion Technology commercialized under the Edison Sonics brand.\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eQuantifiable performance metrics derived from the clinical study:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFAST™ Nanoemulsion (Preliminary Result)\u003c\/th\u003e\n\u003cth\u003eControl Group\/Traditional Edibles\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnset of Effects\u003c\/td\u003e\n\u003ctd\u003eUp to approximately \u003cstrong\u003e50%\u003c\/strong\u003e faster\u003c\/td\u003e\n\u003ctd\u003eStandard onset time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeak Cannabinoid Delivery\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003edouble\u003c\/strong\u003e the delivery\u003c\/td\u003e\n\u003ctd\u003eBaseline delivery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudy Design\u003c\/td\u003e\n\u003ctd\u003eRobust, \u003cstrong\u003e19-day\u003c\/strong\u003e in-clinic, \u003cstrong\u003eeight-arm\u003c\/strong\u003e study\u003c\/td\u003e\n\u003ctd\u003eControl arm for comparison\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eThe technology is characterized by its novelty and validation:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTechnology is \u003cstrong\u003epatent-pending\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eClinical verification through one of the largest pharmacokinetic studies in the cannabis industry, completed in \u003cstrong\u003eJanuary 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eImitability is supported by intellectual property status:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe technology is branded as FAST™ (Fast Acting Soluble Technology).\u003c\/li\u003e\n\u003cli\u003eCommercialization began with Edison Sonics gummies in \u003cstrong\u003eNovember 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eEvidence of organizational capability to commercialize the IP:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEdison Sonics gummies launched with \u003cstrong\u003etwo\u003c\/strong\u003e gummies per pack, containing a total of \u003cstrong\u003e10mg THC + 10mg CBD\u003c\/strong\u003e per pack (\u003cstrong\u003e5mg THC + 5mg CBD\u003c\/strong\u003e per gummy).\u003c\/li\u003e\n\u003cli\u003eProduct availability targeted for all major provinces starting \u003cstrong\u003eearly December\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe technology is the first innovation commercialized leveraging the Product Development Collaboration (“PDC”).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eThe advantage is tied to the IP and market entry timing:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFirst-to-market innovation status as of launch.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrganiGram Holdings Inc. (OGI) - VRIO Analysis: Diversified, Multi-Facility Production Footprint\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides operational flexibility, capacity for growth (adding over \u003cstrong\u003e14,000 kg\u003c\/strong\u003e annually planned), and specialized production hubs.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; several large producers have multiple sites, but OrganiGram’s five distinct facilities offer specialized functions.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; building five specialized, licensed facilities is capital-intensive and time-consuming.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; they are actively optimizing these sites, like moving vape filling to Aylmer for scale efficiencies.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; the physical infrastructure and associated Health Canada licensing are significant barriers to entry.\u003c\/p\u003e\n\u003cp\u003eThe five specialized, licensed facilities contribute to the operational structure:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMoncton, New Brunswick: Flagship facility, indoor cultivation, production capabilities, R\u0026amp;D hub.\u003c\/li\u003e\n\u003cli\u003eLac-Supérieur, Québec: Greenhouse facility specializing in premium cannabis and top-tier hashish.\u003c\/li\u003e\n\u003cli\u003eWinnipeg, Manitoba: Manufacturing facility for edibles and extracts, 51k sq. ft.\u003c\/li\u003e\n\u003cli\u003eAylmer, Ontario: Processing facility (acquired via Motif).\u003c\/li\u003e\n\u003cli\u003eLondon, Ontario: Processing facility (acquired via Motif).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCapacity metrics related to the production footprint:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacility\/Metric\u003c\/td\u003e\n\u003ctd\u003eCultivation Type\/Focus\u003c\/td\u003e\n\u003ctd\u003eCapacity\/Volume Data\u003c\/td\u003e\n\u003ctd\u003eRecent Operational Data\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMoncton Campus\u003c\/td\u003e\n\u003ctd\u003eIndoor Cultivation\u003c\/td\u003e\n\u003ctd\u003eHarvested over \u003cstrong\u003e24,000 kg\u003c\/strong\u003e in Q3.\u003c\/td\u003e\n\u003ctd\u003eAverage THC exceeded \u003cstrong\u003e29%\u003c\/strong\u003e across the facility in Q3.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMoncton Capacity Enhancements\u003c\/td\u003e\n\u003ctd\u003eLED Upgrades\/Optimization\u003c\/td\u003e\n\u003ctd\u003eExpected to increase annual capacity up to \u003cstrong\u003e7,000 kg\u003c\/strong\u003e.\u003c\/td\u003e\n\u003ctd\u003eAdditional 7,300 kg expected from nutrient optimizations\/utilization.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Planned Addition\u003c\/td\u003e\n\u003ctd\u003eCapacity Growth\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e14,000 kg\u003c\/strong\u003e of annual capacity added.\u003c\/td\u003e\n\u003ctd\u003eHistorical target capacity mentioned: approx. \u003cstrong\u003e113,000 kg\u003c\/strong\u003e by end of 2019.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWinnipeg Facility\u003c\/td\u003e\n\u003ctd\u003eManufacturing (Edibles\/Extracts)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e51k sq. ft.\u003c\/strong\u003e manufacturing footprint.\u003c\/td\u003e\n\u003ctd\u003eSupports ready-to-consume product refinement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Efficiency\u003c\/td\u003e\n\u003ctd\u003eOperational Metrics\u003c\/td\u003e\n\u003ctd\u003eAchieved adjusted gross margin of \u003cstrong\u003e37%\u003c\/strong\u003e in Q4 Fiscal 2024.\u003c\/td\u003e\n\u003ctd\u003eRealized \u003cstrong\u003e$9.1 million\u003c\/strong\u003e in annual cost savings in Fiscal 2024.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe organization leverages this footprint for market position:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMaintained number one market share position in Western, Central and Atlantic Canada, including Ontario, Alberta, and B.C. in Q3.\u003c\/li\u003e\n\u003cli\u003eHeld number one positions in vapes, pre-rolls, and concentrates in Q3.\u003c\/li\u003e\n\u003cli\u003eInternational revenue in Q3 reached \u003cstrong\u003e$7.4 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrganiGram Holdings Inc. (OGI) - VRIO Analysis: International Export Agreements \u0026amp; EU-GMP Pathway\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eUnlocks high-margin, regulated international markets, evidenced by $7.4 million in Q3 2025 international revenue. This international revenue represented 10% of the total Q3 2025 net revenue of $70.8 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; many Canadian firms export, but having established supply agreements (Germany, U.K., Australia) and awaiting EU-GMP certification is a key differentiator. To date, seven supply deals have been established in Australia, Germany, Israel, and the UK.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; EU-GMP certification is a rigorous, non-imitable regulatory hurdle that opens doors. The final audit for EUGMP certification at the Moncton Campus was conducted in November 2024, with certification expected in 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; the company is actively managing this pipeline, supported by their investment in Sanity Group in Germany. The Jupiter strategic investment pool has CAD 59 million available to deploy for international strategic investments as of Q3 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained; the regulatory moat provided by GMP certification is a long-term advantage.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric Category\u003c\/th\u003e\n\u003cth\u003eSpecific Data Point\u003c\/th\u003e\n\u003cth\u003eAssociated Value\/Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Revenue Performance (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eInternational Revenue Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Revenue Performance (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eYear-over-Year Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e208%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU-GMP Pathway Status\u003c\/td\u003e\n\u003ctd\u003eFinal Audit Date\u003c\/td\u003e\n\u003ctd\u003eNovember 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU-GMP Pathway Status\u003c\/td\u003e\n\u003ctd\u003eExpected Certification Year\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGermany Market Access (Sanity Group)\u003c\/td\u003e\n\u003ctd\u003eInvestment Amount (Initial)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e€14 million\u003c\/strong\u003e (approx. \u003cstrong\u003eC$21 million\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGermany Market Access (Sanity Group)\u003c\/td\u003e\n\u003ctd\u003eSanity Group German Market Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGermany Market Access (Sanity Group)\u003c\/td\u003e\n\u003ctd\u003ePharmacies in Distribution Network\u003c\/td\u003e\n\u003ctd\u003eOver \u003cstrong\u003e2,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUK Export Agreement (Avida Medical)\u003c\/td\u003e\n\u003ctd\u003eTotal Flower Supply Commitment (3 Years)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,700 kilograms\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic Investment Capacity\u003c\/td\u003e\n\u003ctd\u003eJupiter Pool Available Funds (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eCAD 59 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eEU-GMP Application Timeline:\u003c\/strong\u003e Application submitted in Q1 Fiscal 2024; preliminary audit completed in February 2024.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eSanity Group Investment Structure:\u003c\/strong\u003e Initial €14 million comprised of €11.5 million unsecured convertible note and €2.5 million equity purchase, with an option for an additional €3 million.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003e\u003cstrong\u003eUK Supply Commitment Detail:\u003c\/strong\u003e The Avida Medical agreement includes 500 kg expected to be delivered in the first year.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrganiGram Holdings Inc. (OGI) - VRIO Analysis: Strategic U.S. Hemp-Derived Beverage Market Access\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProvides an immediate, legal revenue stream in the massive U.S. market through the Collective Project acquisition, now in 25 states via direct-to-consumer e-commerce. The U.S. hemp-derived THC beverage market has already surpassed $1 billion in retail sales and is projected to reach $4 billion by 2028.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; while many firms have U.S. aspirations, OrganiGram is actively generating revenue in the hemp-derived THC beverage space, evidenced by International Revenue of $7.4 million in Q3 Fiscal 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; the specific entry point via a strategic acquisition, with upfront consideration of approximately C$6.2 million and potential earnouts up to C$24 million, and existing distribution is not easily copied.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; they have successfully integrated this segment to contribute to their record Q3 2025 results, where Net Revenue reached $70.8 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary; U.S. federal regulation changes could rapidly alter the landscape, but current access is valuable.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFinancial and Operational Metrics Related to U.S. Access and Q3 2025 Performance\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. DTC Availability\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25 states\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSubsequent to Q3 Fiscal 2025 end\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 Fiscal 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Revenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e208%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 Fiscal 2025 vs Q3 Fiscal 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Net Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$70.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ3 Fiscal 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Cash Position\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$85.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of Q3 Fiscal 2025 end\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected U.S. Hemp Beverage Market Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBy 2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eSpecific U.S. Direct-to-Consumer States\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eArkansas\u003c\/li\u003e\n\u003cli\u003eFlorida\u003c\/li\u003e\n\u003cli\u003eIllinois\u003c\/li\u003e\n\u003cli\u003eNew Jersey\u003c\/li\u003e\n\u003cli\u003eOhio\u003c\/li\u003e\n\u003cli\u003eTexas\u003c\/li\u003e\n\u003cli\u003eWyoming\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrganiGram Holdings Inc. (OGI) - VRIO Analysis: Acquisition Integration \u0026amp; Synergy Realization (Motif)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Drives cost reduction and scale, with synergies already at \u003cstrong\u003e$4.2 million\u003c\/strong\u003e to date, tracking toward a \u003cstrong\u003e$15 million\u003c\/strong\u003e annualized target. The integration is expected to improve the adjusted gross margin, which was \u003cstrong\u003e33%\u003c\/strong\u003e in Q2 Fiscal 2025 (reflecting Motif's margin before full synergy realization), compared to Organigram's standalone adjusted gross margin of \u003cstrong\u003e37%\u003c\/strong\u003e in the same quarter.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Reporting Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Acquisition Cost\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eC$90 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eConsisting of C$50 million cash and C$40 million in common shares at close.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContingent Consideration\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003eC$10 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePayable in common shares conditional on share price performance within 12 months of transaction.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Synergy Estimate\u003c\/td\u003e\n\u003ctd\u003eIn excess of \u003cstrong\u003e$10 million\u003c\/strong\u003e annualized\u003c\/td\u003e\n\u003ctd\u003eEstimated to be realized over approximately 24 months post-acquisition.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevised Synergy Target\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$15 million\u003c\/strong\u003e annualized\u003c\/td\u003e\n\u003ctd\u003eIncreased from the prior estimate of $10 million.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSynergies Realized to Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of the Q3 Fiscal 2025 results announcement.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnualized Synergy Run-Rate\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$11 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eReported run-rate based on synergies realized to date as of Q3 Fiscal 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; M\u0026amp;A is common, but achieving significant, measurable synergies is not guaranteed.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the specific synergy capture from the Motif acquisition is unique to OrganiGram.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; despite minor integration hiccups, they are on track to meet the synergy goal, showing strong post-merger management.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eQ2 Fiscal 2025 Net Revenue: \u003cstrong\u003e$45.7 million\u003c\/strong\u003e (approximately \u003cstrong\u003eCA$65.6 million\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eQ3 Fiscal 2025 Net Revenue: \u003cstrong\u003e$51.14 million\u003c\/strong\u003e (approximately \u003cstrong\u003e$70.8 million CAD\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eQ2 Fiscal 2025 Adjusted EBITDA: \u003cstrong\u003eCA$4.9 million\u003c\/strong\u003e, compared to a loss of $1 million a year ago.\u003c\/li\u003e\n\u003cli\u003eQ3 Fiscal 2025 Adjusted Gross Margin: \u003cstrong\u003e34%\u003c\/strong\u003e of net revenue.\u003c\/li\u003e\n\u003cli\u003eTotal Cash Position (as of Q2 Fiscal 2025): Approximately \u003cstrong\u003e$83.4 million\u003c\/strong\u003e and negligible debt.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the synergy window closes once the \u003cstrong\u003e$15 million\u003c\/strong\u003e target is fully realized.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrganiGram Holdings Inc. (OGI) - VRIO Analysis: Proprietary Genetics Access (via Phylos Bioscience investment)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eProprietary Genetics Access (via Phylos Bioscience investment)\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Component\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eSupporting Data\/Metrics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eSecures a pipeline for future high-value, differentiated genetics, such as exclusive access to THCV.\u003c\/td\u003e\n\u003ctd\u003eInvestment up to \u003cstrong\u003e$8 million\u003c\/strong\u003e convertible loan. Exclusive Canadian rights to THCV cultivars until \u003cstrong\u003eMay 2028\u003c\/strong\u003e. Cultivars like Joyride have THCV concentrations of \u003cstrong\u003e16+%\u003c\/strong\u003e. Initial THCV gummy SKU was \u003cstrong\u003e1:1\u003c\/strong\u003e THC:THCV (\u003cstrong\u003e10mg THC + 10mg THCV\u003c\/strong\u003e per pack).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eHigh; exclusive access to specific, cutting-edge genetics like THCV is rare in the broader market.\u003c\/td\u003e\n\u003ctd\u003eOrganigram is currently the only Canadian licensed producer believed to be cultivating and extracting from THCV flower in-house. Access to high potency \u003cstrong\u003eCBG, CBC, and CBDV\u003c\/strong\u003e cultivars included in expanded license.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability\u003c\/td\u003e\n\u003ctd\u003eHigh; exclusivity clauses in investment agreements are difficult for competitors to break.\u003c\/td\u003e\n\u003ctd\u003eExclusive rights to commercialize THCV derived from Phylos' cultivars until \u003cstrong\u003eMay 2028\u003c\/strong\u003e. Initial investment tranche was \u003cstrong\u003e$3.25 million\u003c\/strong\u003e, with a total commitment of up to \u003cstrong\u003e$8 million\u003c\/strong\u003e. Loan accrues PIK interest up to a cap of \u003cstrong\u003e11%\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eModerate; the benefit is currently potential, requiring successful R\u0026amp;D translation into commercial products.\u003c\/td\u003e\n\u003ctd\u003ePhylos required to deliver \u003cstrong\u003e21\u003c\/strong\u003e unique auto-flower seed varietals by \u003cstrong\u003eSeptember 30, 2024\u003c\/strong\u003e, and a second cohort of \u003cstrong\u003e21\u003c\/strong\u003e by \u003cstrong\u003eJanuary 31, 2025\u003c\/strong\u003e. Organigram launched \u003cstrong\u003esix\u003c\/strong\u003e THCV SKUs across \u003cstrong\u003efour\u003c\/strong\u003e formats. Expected launch of initial products as early as \u003cstrong\u003esummer of 2023\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eSustained, as long as the exclusive partnership with Phylos Bioscience remains intact.\u003c\/td\u003e\n\u003ctd\u003eExclusive rights last until \u003cstrong\u003eMay 2028\u003c\/strong\u003e. Total advanced to date is \u003cstrong\u003eUS $7 million\u003c\/strong\u003e, with \u003cstrong\u003eUS $1 million\u003c\/strong\u003e remaining contingent on a milestone by \u003cstrong\u003eMarch 31, 2026\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDetails on Genetics and Product Rollout:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eExclusive Canadian rights to THCV cultivars including Get ST Done (\u003cstrong\u003e1:3\u003c\/strong\u003e THC:THCV) and Joyride (\u003cstrong\u003e1:1\u003c\/strong\u003e THC:THCV).\u003c\/li\u003e\n\u003cli\u003eOne gummy SKU offered a \u003cstrong\u003e1:2\u003c\/strong\u003e THC:THCV ratio (\u003cstrong\u003e10mg THC + 20mg THCV\u003c\/strong\u003e per pack).\u003c\/li\u003e\n\u003cli\u003ePhylos has developed proprietary high-THCV genetics in various THC:THCV ratios.\u003c\/li\u003e\n\u003cli\u003eOrganigram's investment is structured as a convertible loan.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrganiGram Holdings Inc. (OGI) - VRIO Analysis: Strong Balance Sheet \u0026amp; Strategic Capital Pool (Jupiter)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a war chest of approximately \u003cstrong\u003e$85.9 million\u003c\/strong\u003e total cash available for strategic international deployment, ensuring liquidity and funding for growth as of June 30, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High; having \u003cstrong\u003enegligible debt\u003c\/strong\u003e and significant cash of \u003cstrong\u003e$85.9 million\u003c\/strong\u003e total cash (including restricted cash) as of June 30, 2025, is rare in the capital-intensive cannabis sector.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; building this level of cash reserves while achieving positive Free Cash Flow of \u003cstrong\u003e$5.0 million\u003c\/strong\u003e in Q3 2025 is organizationally difficult.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the capital is explicitly positioned for growth, evidenced by the \u003cstrong\u003e$7.4 million\u003c\/strong\u003e in International Revenue generated in Q3 2025 and strategic moves like the U.S. hemp-derived THC beverage launch.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; financial strength acts as a buffer and an offensive weapon for opportunistic M\u0026amp;A. The ability to generate positive Free Cash Flow of \u003cstrong\u003e$5.0 million\u003c\/strong\u003e in the quarter supports this offensive capability.\u003c\/p\u003e\n\u003cp\u003eKey Financial Metrics for Q3 Fiscal 2025 (Ended June 30, 2025):\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount (CAD)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Cash (as of June 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$85.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnrestricted Cash (as of June 30, 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$35.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNegligible\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$70.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree Cash Flow\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Cash from Operating Activities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternational Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe strategic deployment intent is further supported by market positioning:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMarket Share in Canada: \u003cstrong\u003e#1\u003c\/strong\u003e in vapes, \u003cstrong\u003e#1\u003c\/strong\u003e in pre-rolls, \u003cstrong\u003e#1\u003c\/strong\u003e in milled flower, and \u003cstrong\u003e#1\u003c\/strong\u003e in concentrates.\u003c\/li\u003e\n\u003cli\u003eInternational Sales Growth (YoY): \u003cstrong\u003e+208%\u003c\/strong\u003e to $7.4 million in Q3 Fiscal 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eOrganiGram Holdings Inc. (OGI) - VRIO Analysis: Multi-Segment, Tiered Brand Portfolio\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows OrganiGram Global to capture market share across various consumer preferences, from value (SHRED) to premium (Edison). The SHRED brand alone generated $225 million in annual retail sales as of the end of Q4 Fiscal 2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; many competitors have brands, but OrganiGram’s portfolio is deeply embedded, holding #1 share in several key categories post-Motif acquisition. The combination resulted in the #1 market share position in the Canadian recreational cannabis market at 12.4%.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderate; building brand equity takes significant time and marketing spend, though the brands themselves can be bought. The upfront consideration for acquiring Motif Labs, which bolstered the portfolio, was $90 million (comprising $50 million in cash and $40 million in common shares).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the company is actively managing and launching new products across these brands, like SHRED Max10 Party Pack. The integration of Motif is expected to realize cost synergies estimated to exceed $10 million over approximately 24 months.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; deep brand loyalty and category dominance are hard to erode quickly. The company reported Fiscal 2024 net revenue of $159.8 million.\u003c\/p\u003e\n\n\u003cp\u003eThe brand portfolio strength is evident across key segments:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eBrand\/Segment Focus\u003c\/td\u003e\n\u003ctd\u003eKey Metric\u003c\/td\u003e\n\u003ctd\u003eValue\/Share\u003c\/td\u003e\n\u003ctd\u003eReporting Period\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSHRED (Value)\u003c\/td\u003e\n\u003ctd\u003eAnnual Retail Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$225 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEnd of Q4 Fiscal 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMotif\/BOXHOT (Vape)\u003c\/td\u003e\n\u003ctd\u003eCanadian Vape Market Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e21.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePre-acquisition context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMotif\/DEBUNK (Infused Pre-roll)\u003c\/td\u003e\n\u003ctd\u003eCanadian Infused Pre-roll Market Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePre-acquisition context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Company\u003c\/td\u003e\n\u003ctd\u003eNet Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$159.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Company (Post-Acquisition)\u003c\/td\u003e\n\u003ctd\u003eNational Market Share\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePost-Motif acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eSpecific market share data points demonstrating category depth include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eOrganigram held the #1 position in milled flower, #1 in hash, and #1 in pure CBD gummies in Q3 Fiscal 2024.\u003c\/li\u003e\n\u003cli\u003eIn Q3 Fiscal 2025, the company held 20.4% of the national vape segment and 8.3% of the pre-roll segment.\u003c\/li\u003e\n\u003cli\u003eFlower market share grew to 10.6% in Q3 Fiscal 2025, up 60 basis points from Q2.\u003c\/li\u003e\n\u003cli\u003eRecord market share in New Brunswick reached 25.8% in Q3 Fiscal 2024.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516222529685,"sku":"ogi-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ogi-vrio-analysis.png?v=1740202708","url":"https:\/\/dcf-model.com\/fr\/products\/ogi-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}